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COMPARISON OF DRUG TYPES IN INCIDENT REPORTS AMONG 
TEACHING HOSPITALS IN JAPAN
Hirose M1, Egami K1, Ohama K1, Tsuda Y1, Honda J1, Shima H1, Takemura T2, Okamoto 
K2, Yoshihara H2, Oh EH3
1Saint Mary’s Hospital, Kurume, Japan, 2Kyoto University Hospital, Kyoto, Japan, 3Hyupsung 
University, Hwaseong-Si, Gyeonggi-Do, South Korea
OBJECTIVES: Although incident reporting is very useful for securing patient safety, 
there are no previous studies comparing incident reports by extracting Drug Names 
from them. METHODS: We used 5,647 consecutive incident reports from Saint 
Mary’s Hospital (SMH) and 2,816 reports from Shimane University Hospital (SUH) 
between April ‘06 and March ‘08, and 3,087 reports from Kyoto University Hospital 
(KUH) between March ‘04 and August ‘05. RESULTS: 1) The number of top ﬁve 
ranking reports at SMH are 279 (Central Nervous System drugs, 4.9%(279/5647)), 
231 (Anti-diabetic drugs, 4.1%), 222 (Cardiovascular drugs, 3.9%), 127 (Anti-infec-
tive drugs, 2.2%) and 125 (Gastrointestinal drugs, 2.2%), in order. The numbers of 
those at KUH are 163 (CNS drugs, 5.3%), 130 (Cardiovascular drugs, 4.2%), 106 
(Gastrointestinal and Anti-infective drugs,each 3.4%), and 89 (Anti-diabetic drugs, 
2.9%). and the number of those at SUH are 244 (CNS drugs, 8.7%), 156 (Anti-dia-
betic drugs, 5.5%), 116 (Drugs affecting coagulation, 4.1%), 86 (Cardiovascular 
drugs, 3.1%), and 75 (Opiates, 2.7%). 2) CNS, Cardiovascular drugs are includued 
in the top ﬁve ranking drugs at all three hospitals. Gastrointestinal and Anti-infective 
drugs are included at SMH and KUH in top ﬁve. 3) CNS drugs featured much more 
at SMH and KUH, resulting from the higher proportion of the elderly inpatients at 
SUH in rural than those at SMH or KUH in urban. 4) The numbers with Cardiovas-
cular and Anti-diabetic drugs at all hospitals are huge, because Japanese patients are 
affected with cardiovascular disease and diabetes as adult lifestyle diseases. CONCLU-
SIONS: Different characteristics of the study areas might lead to these results. Further 
study should be conducted related with this topic. Furthermore, it would be very 
important for junior residents and new nursing stuff to be taught with emphasis on 
the careful attention with the above drugs through residency and education programs 
have a higher tendency to be involved with errors.
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CONSUMERS’ KNOWLEDGE OF GENERIC OTCS: A PHARMACIST 
INTERVENTION STUDY
Exaus CJ, Sangasubana N, Borja-Hart N, Alvarez G, Selagea AR, Rodriguez J, Rabionet S, 
Calderon JL
Nova Southeastern University College of Pharmacy, Fort Lauderdale, FL, USA
OBJECTIVES: To test the efﬁcacy of pharmacist interventions to increase consumers’ 
knowledge of generic Over-the-Counter (OTC) products. METHODS: A randomized-
controlled post-test only design was used in a judgment sample of adults recruited 
from a university-afﬁliated pharmacy excluding employees and students. Subjects were 
randomized into: 1) an intervention group receiving a pharmacist-developed pamphlet 
utilizing FDA information about generic drugs; 2) an intervention group receiving a 
5-minute pharmacist consultation about generic drugs with pamphlet reinforcement; 
and 3) a control group receiving neither intervention. Subjects completed a post-
intervention 7-item True/False questionnaire testing their knowledge on product dif-
ferences (2 items: price; physical appearance) and similarities (5 items: active 
ingredients; dosage form; safety; performance; quality) between generic and branded 
OTCs. A composite objective knowledge score (0–100) was calculated [(number of 
subjects’ correct responses/7)x100]. Student’s t-test, chi-square and analysis of vari-
ance (p < 0.05) were conducted to test the effects of the pharmacist interventions on 
consumers’ knowledge. RESULTS: A sample of 157 subjects completed the study 
(pamphlet = 53; pharmacist consultation = 51; control = 53). Nearly 71% were female 
with the average age being 47.6 (S.D. = 17.7) years. The majority (45.2%) had some 
college education, 24.5% high school or less, and 29.3% completing college. There 
were no signiﬁcant group differences in subjects’ sociodemographic characteristics. 
The average objective knowledge score was 84.4 (S.D. = 23.8), i.e., pamphlet = 90.9; 
pharmacist = 92.2; control = 67.7. Subjects in both intervention groups scored signiﬁ-
cantly higher than in the control group. However, the knowledge score difference 
between those receiving pamphlet only and pharmacist consultation with pamphlet 
was not signiﬁcant. CONCLUSIONS: The study’s educational interventions, whether 
in the form of a written pamphlet or a combination of a verbal pharmacist consulta-
tion with pamphlet reinforcement, signiﬁcantly increased consumers’ knowledge of 
generic OTCs. These ﬁndings indicate the importance of pharmacist involvement and 
participation in both the design and implementation of written and verbal patient 
education of generic OTCs.
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CMS VS. NICE COVERAGE OF TECHNOLOGIES: HOW DO THEY 
COMPARE?
Kamae MS, Chambers JD, Neumann PJ
Tufts Medical Center, Boston, MA, USA
OBJECTIVES: The US Centers for Medicare and Medicaid Services (CMS) and the 
UK’s National Institute for Health and Clinical Excellence (NICE) issue coverage 
decisions or guidances about medical technology. We compared the overlap in the 
technologies considered and the decisions/recommendations between the two agencies. 
METHODS: We reviewed all NCDs (n = 138) posted on the CMS website between 
1999 through 2009 and all guidances (n = 613) posted on NICE’s website since 1999. 
We included all types of NICE guidances, including cancer service guidances, clinical 
guidelines, interventional procedures, public health guidances, and technology 
appraisals. We compared CMS and NICE documents to determine overlap in the 
technologies considered and the consistency of the recommendations. RESULTS: Of 
138 CMS NCDs, 58 pertained to technologies also evaluated by NICE. Medical 
procedures (n = 14) and medical devices (n = 12) were the most common overlapping 
technologies. Pharmaceuticals (n = 3) least frequently overlapped, in large part because 
Medicare rarely uses NCD for drugs. In terms of recommendations for overlapping 
technologies, 79% of NCDs and 93% of NICE guidances were favorable. 86% of 
overlapping technologies had the same direction of the recommendation, though there 
were some differences in the target population and other details. In the 8 “discrepant” 
decisions (where CMS and NICE recommendations disagreed), most often CMS issued 
a non-coverage decision while NICE supported the technology or allowed clinicians 
to use the technology with special arrangements. These include technologies such as 
screening computed tomography colonography for colorectal cancer and lumbar arti-
ﬁcial disc replacement for the patients over sixty years of age. CONCLUSIONS: Less 
than half of the technologies that Medicare considered in NCDs were also evaluated 
in NICE guidances. Where the two agencies evaluated the same technologies, recom-
mendations were mostly consistent. However, where there were disagreements, CMS 
tended to be more restrictive than NICE.
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ARE GOVERNMENT BASED REIMBURSEMENT PROGRAMS PERCEIVED 
BETTER OR WORSE COMPARED TO COMMERCIAL MANAGED CARE 
INSURANCE PAYERS BY PHARMACISTS?
Patel J, Goyal RK, Sansgiry S
University of Houston, Houston, TX, USA
OBJECTIVES: Reimbursement issues in Medicare Part D and Medicaid plans have 
been argued to cause ﬁnancial instability in pharmacies. Is reimbursement amount and 
processing time different in the three major health insurance providers, namely Medi-
care part D, Medicaid and commercial managed care insurance payers? METHODS: 
A cross-sectional survey of pharmacists processing claims in independent pharmacies 
in the Houston metropolitan area was conducted using a 5-point Likert-scale question-
naire. Reimbursement rate was deﬁned as the actual percentage of claimed amount 
received from insurance payers. Reimbursement processing time was deﬁned as the 
number of days taken to receive reimbursement after claim adjudication. The question-
naire addressed issues with respect to adequacy and improvement of reimbursement 
rates and processing times across three insurance payers. Further satisfaction and 
whether pharmacists encountered cash-ﬂow problems due to reimbursement issues 
was obtained. Descriptive analyses were conducted and the analysis of variance was 
performed, followed by Tukey’s multiple comparison method to identify differences 
between payment sources. RESULTS: Pharmacists, in general, disagreed that the 
reimbursement rate and processing time were adequate in any of the three categorized 
payment processors. They perceived that the mean (SD) reimbursement rate from 
commercial managed care plans (2.05 (0.87), p < 0.001) was not adequate compared 
to Medicare Part D (2.6 (0.9)), and Medicaid plans (2.75 (0.95)). Pharmacists’ per-
ceived processing time was better in Medicaid plans (3.05 (1.04), p < 0.001) as 
compared to Medicare Part D (2.5 (0.98)), and commercial managed care plans (2.64 
(0.87)). They were dissatisﬁed with the process of reimbursement which had created 
cash ﬂow problems for their pharmacy and this perception was consistent across all 
payers. CONCLUSIONS: The reimbursement rate and the processing time for pre-
scription drug claims were believed to be inadequate in all three payment processors. 
Government programs were perceived to be better as compared to commercial 
managed care insurance programs.
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LISTING AND REIMBURSEMENT OF NEW DRUGS IN NATIONAL 
HEALTH INSURANCE—AN EMPIRICAL EXPERIENVCE OF TAIWAN
Huang WF1, Hsieh CF1, Chen GT2
1Institute of Health & Welfare Policy, National Yang-Ming University, Taipei, Taiwan, 
2Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan
OBJECTIVES: We aim to present the empirical experience of new drug listing and 
reimbursement under Taiwan’s National Health Insurance (NHI), and to analyze the 
performance of such mechanism. We also attempt to assess its impact to the research-
based pharmaceutical company and the public access to pharmaceutical innovations. 
METHODS: The materials are based on the documentation of Taiwan’s NHI Drug 
Review Committee (DRC) over 11 years period (1996∼2006). We deﬁned the criteria 
of pricing methods into 9 categories: International Price Comparison, Comparison 
with Similar Products with Equivalent Therapeutic Effects, Price Proportion Method, 
Price Addition, Orphan Drugs, The Lowest Available International Price, Cost Analy-
sis, Grouping and Others. RESULTS: The total number of new drugs that applied for 
NHI listing and reimbursement during 1996∼2006 was 787, and the number of peti-
tion cases was 325(41%). The total number of new drugs with ﬁnal pricing decisions 
in this study was 566. Among them, 298 items were issued with reimbursement price 
without petition, and the remaining 268 new drugs received their reimbursement 
prices after petition on initial pricing decisions. The approved price was averaged 74% 
of the international median prices, and was only 65% of international median prices 
among petition cases. The top three methods of pricing are Price Proportion Method 
(37.1%), Equivalent Therapeutic Effect with Similar Product (23.5%), and Interna-
tional Price Comparison (14.7%). Although NHI continues to facing ﬁnancial crisis 
in the past 10 years, the price of reimbursement remained approximately 71% of their 
respective application prices during all the period. CONCLUSIONS: The policy direc-
tion of NHI pricing and reimbursement is to ensure that resources serve the highest 
priorities of the population’s health needs in an efﬁcient way. It is worthwhile to 
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evaluate whether the pricing and reimbursement decision of new drugs in Taiwan’s 
NHI to fulﬁll the transparency and the expectation of public beneﬁts.
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ASSESSING THE IMPACT AND VALUE OF HEALTH OUTCOMES 
PUBLICATIONS USING CITATION DATA FROM INDICES OF 
SCHOLARLY LITERATURE
Fisher DL1, Bakken R2
1Lilly USA, LLC, Indianapolis, IN, USA, 2Lilly USA, LLC, Rochester, MN, USA
OBJECTIVES: Clinical trial data are typically published in journals with a therapeutic 
area focus and accessed by researchers and health care providers (HCPs) for the 
purposes of sharing knowledge and improving outcomes for patients. Pharmacoeco-
nomic and health outcomes data are published for the same reasons, but often are 
most relevant to payers and other managed care decision makers. Yet there is limited 
knowledge of what factors make health outcomes publications most valuable to payers 
and HCPs and of how health outcomes decisions are inﬂuenced by publications. Our 
goal was to assess the impact of health outcome-related publications using literature 
citation data from two major web search engines that index scholarly literature. We 
envision that enhanced understanding of how health outcomes publications are sub-
sequently used may improve the quality of future publications and maximize useful-
ness to health care providers, payers, and patients. METHODS: In order to determine 
which types of papers were most read or most used to inform subsequent studies, we 
identiﬁed a sample of health outcomes papers published within the past 5 years and 
used Google Scholar and SciSearch to collect data on the number of times these 
publications were cited in subsequent research papers. RESULTS: Number of citations 
ranged from 0–57 per publication. Average number of citations was 10.2 per publica-
tion. Articles in therapeutically focused journals as well as cross-therapeutic health 
outcomes focused journals were frequently cited. CONCLUSIONS: These ﬁndings 
contribute to a growing understanding of the value of health outcomes publications 
for payers, health care decision-makers, and researchers in academia, government, and 
industry.
PHP73
IMPACT OF PHARMACEUTICAL REFORM AND ISSUES INVOLVED IN 
SOUTH KOREA’S NHI
Yang BM
Seoul National University, Seoul, South Korea
OBJECTIVES: To assess the impact of recent pharmaceutical reform in South Korea 
METHODS: Descriptive analysis RESULTS: The South Korean National Health 
Insurance (NHI) system recently introduced a reform in pharmaceutical reimburse-
ment, with the purpose of increasing rational resource use in drug spending. The new 
policy aims to take the cost-effectiveness and budget impact of newly introduced drugs 
into account in payment decisions, and to re-evaluate the economic rationale of for-
merly existing drugs in the NHI drug reimbursement list. Under the new policy, a new 
drug goes through two stages; the ﬁrst stage of reimbursement decision, and the second 
stage of price negotiation. That is, once a drug is determined to be in the reimburse-
ment list, then it will go through a price negotiation process. Recent data reveal that 
the new policy, called the PLSP(positive list system policy), somewhat reduced the rate 
of reimbursement listing and successful price negotiations. The impact of PLSP would 
be diverse, including economic effects, access to new drugs, and dynamic efﬁciency. 
It is also true that the new policy faces challenges and confronts a number of issues, 
such as availability of data, utility measurement, threshold, modeling, degree of evi-
dence use, and decision-making process. CONCLUSIONS: This paper will provide a 
review of the ﬁrst three years policy outcomes, and attempt to assss the Korean PLSP 
in terms of the challenges and issues mentioned above.
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RISK SHARING: WHAT’S AT RISK AND WHAT’S BEING SHARED
Cano-Chancel A1, Long M2, Sparrowhawk K2
1Cambridge University, Ecole Polytechnique-France, Paris, France, 2PriceSpective LLC, 
London, UK
OBJECTIVES: Health care providers across the globe are facing the signiﬁcant ﬁnan-
cial challenge of funding new, innovative and expensive medicines for populations 
who are living longer and demanding better care. This funding dynamic has not only 
increased immediate ﬁnancial pressures on health care systems but also raises the level 
of risk associated with uncertainty around both clinical efﬁcacy and budgetary impact. 
To address this, payers are raising market access hurdles and implementing new cost 
containment measures. In response, industry is developing new pricing and reimburse-
ment strategies. Risk sharing is one example of how payers are trying to ensure value 
for money. This study assesses whether risk-sharing agreements have the necessary 
components to become sustainable in the coming years. METHODS: Secondary 
research was conducted to categorize and assess the types of risk-sharing agreements 
currently in place. Primary research was then used to obtain both payer and industry 
insight about the success and shortcomings of risk sharing and to anticipate how 
risk-sharing agreements are likely to evolve in the future. RESULTS: Risk sharing is 
often a misnomer. While some risk sharing agreements are developed to address 
uncertainty around clinical evidence, the majority of them focus on reducing the 
ﬁnancial impact of new products independent of the clinical beneﬁt. CONCLUSIONS: 
This analysis suggests that there is no one perfect method of risk sharing. In order for 
risk sharing to transition from a trend into a sustainable method of ﬁnancing new 
therapies, a careful understanding of the risk a new therapy poses and how to best 
mitigate that risk is needed.
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A FRAMEWORK TO ASSIST PHARMACEUTICAL COMMERCIALIZATION 
TEAMS IN EFFICIENTLY ALLOCATING RESOURCES TO GENERATE 
EVIDENCE OF PRODUCT VALUE TO SUPPORT GLOBAL MARKET 
ACCESS ACROSS DIVERSE PAYER ENVIRONMENTS
Rizzo M, Zieses C
Double Helix Consulting US, New York, NY, USA
OBJECTIVES: A common goal among biopharmaceutical product development 
teams is incorporating market access considerations, e.g., clinical trial and outcomes 
data, health technology assessment (HTA) organization requirements, and pricing 
scenarios earlier in commercial planning in order to properly align product value with 
payer motivations. This research investigates the utility of a framework for commer-
cial teams to assess therapeutic category and product access opportunities; and to do 
so simultaneously in heterogeneous market access environments. The resulting graphi-
cal framework can be used by pharmaceutical ﬁrms to evaluate product positioning 
relative to various market access scenarios in order to inform product development 
and resource investment decisions. METHODS: A simpliﬁed payer value equation 
[(efﬁcacy + safety + burden of disease)/(product price—cost offsets)], is used to 
develop a graph to assess therapeutic areas and products relative to market access 
thresholds. Products are plotted using product value (y-axis) and a combination of 
disease burden and unmet medical need (x-axis). Market access thresholds are plotted 
as curves which represent the level of product innovation required to achieve various 
levels of market access. Movement across thresholds depicts signiﬁcant change in that 
product’s market access (e.g., non-reimbursed versus reimbursed). The position of 
market access thresholds can be estimated by deﬁning market access to existing 
products within individual payer systems. Analyzing product positioning simultane-
ously in multiple markets can be achieved by overlaying such graphs and aligning 
them along similar market access thresholds. RESULTS: This framework can be used 
to illuminate the level of product innovation required to meet the increasingly strin-
gent requirements for market access and inform ﬁrms’ investment decisions. CON-
CLUSIONS: Market access environments are complex and dynamic. Assessing 
therapeutic category and the attributes of new medicines relative to market access 
thresholds can inform pharmaceutical ﬁrms’ strategies to generate evidence of product 
value that are aligned with payer priorities.
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DRUG POLICY IN SLOVAKIA: IMPACT OF PRICING AND 
REIMBURSEMENT REFORMS
Glatz P1, Ilavska A2, Hloska A3, Filko M4
1ISPOR local chapter Slovakia, Bratislava, Slovak Republic, 2Medispektrum, Bratislava, Slovak 
Republic, 3Ministry of Health, Bratislava, Slovak Republic, 4Ministry of Finance, Bratislava, 
Slovak Republic
OBJECTIVES: To look into the impact of the drug policies in the Slovak Republic in 
2006–2009. To evaluate drug policy in terms of drugs’ accessibility, extent of patients’ 
co-payments and introduction of innovative drugs. To compare market developments 
in Slovakia to its neighbors, and EU/OECD countries. METHODS: We calculated the 
impact of several regulatory measures on the size of the market and health insurance 
expenditure: a) Lowering the VAT for drugs from 19% to 10% b) ﬂat price cut (−6.6% 
and −7.4%) c) introduction of degressive mark-up for wholesalers and for pharmacies 
d) two rounds of the international reference pricing.The data on drugs consumption 
were from national databases IMS Health and Pharmadata Ltd. We paired these data 
with reimbursement lists published by Slovak Ministry of Health. We compared trends 
in the Slovak drug market to market trends in neighboring countries and to OECD/
EU markets. RESULTS: In 2006 through 2009, the actual calculated savings on 
publicly-covered drugs reached EUR 160 mil due to the ﬂat price cuts, 385 mil due 
to two international reference pricing rounds and EUR 40 mil due to the degressive 
mark-up. The total volume of the Slovak market in 2009 was 31080 mil in manufac-
turers’ prices, in a country of 5,4 mil inhabitants. Consumption of drugs per capita 
reached app. 3200. CONCLUSIONS: Slovak drug policy was able to signiﬁcantly 
decrese the share of pharma expenditure in total health expenditure while increasing 
access new to drugs. Annual growth of the market in the period averaged 6.3% (1.4% 
in 2009), share of drugs in total health expenditure fell from 37% to 27%%, more 
than 100 new molecules s entered the market, and co-payments are astable app. 12% 
of total drug expenditure. We noticed this trend of decreasing market growth also in 
west European countries, but in middle-east European countries the growth of drug 
market was increasing by more than 10% also in 2009.
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AN EMPIRICAL INVESTIGATION OF MEDICAL LOSS RATIO
Karaca Z
George Washington University & Avalere Health LLC, Washington, DC, USA
OBJECTIVES: The objective of this study is to empirically investigate how the medical 
loss ratio (MLR) changes over time and what factors contribute to that change for 
patients enrolled to Medicare Advantage Special Need Plans. METHODS: We used a 
data supplied by a Medicare Advantage Special Need Plan, which include enrollees’ 
monthly premiums and expenses. The data also provide enrollees’ demographic infor-
mation and CMS risk scores and information regarding facilities and providers par-
ticipating in this plan. We deﬁned MLR as the total amount of revenues from health 
insurance premiums that is spent to pay for the medical services covered by the plan. 
Next, we created a panel data structure and deployed multilevel econometric models 
in our analysis. Finally, we used Hausman test to evaluate the signiﬁcance of ﬁxed-
effect estimators versus the alternative random-effect estimators. RESULTS: We found 
